Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage...
Uložené v:
| Vydané v: | The lancet oncology Ročník 17; číslo 3; s. 367 - 377 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
Elsevier Ltd
01.03.2016
Elsevier Limited |
| Predmet: | |
| ISSN: | 1470-2045, 1474-5488, 1474-5488 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-positive breast cancer.
We did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 495 centres in Europe, Asia, Australia, New Zealand, and North and South America. Eligible women (aged ≥18 years, or ≥20 years in Japan) had stage 1–3 HER2-positive breast cancer and had completed neoadjuvant and adjuvant trastuzumab therapy up to 2 years before randomisation. Inclusion criteria were amended on Feb 25, 2010, to include patients with stage 2–3 HER2-positive breast cancer who had completed trastuzumab therapy up to 1 year previously. Patients were randomly assigned (1:1) to receive oral neratinib 240 mg per day or matching placebo. The randomisation sequence was generated with permuted blocks stratified by hormone receptor status (hormone receptor-positive [oestrogen or progesterone receptor-positive or both] vs hormone receptor-negative [oestrogen and progesterone receptor-negative]), nodal status (0, 1–3, or ≥4), and trastuzumab adjuvant regimen (sequentially vs concurrently with chemotherapy), then implemented centrally via an interactive voice and web-response system. Patients, investigators, and trial sponsors were masked to treatment allocation. The primary outcome was invasive disease-free survival, as defined in the original protocol, at 2 years after randomisation. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00878709.
Between July 9, 2009, and Oct 24, 2011, we randomly assigned 2840 women to receive neratinib (n=1420) or placebo (n=1420). Median follow-up time was 24 months (IQR 20–25) in the neratinib group and 24 months (22–25) in the placebo group. At 2 year follow-up, 70 invasive disease-free survival events had occurred in patients in the neratinib group versus 109 events in those in the placebo group (stratified hazard ratio 0·67, 95% CI 0·50–0·91; p=0·0091). The 2-year invasive disease-free survival rate was 93·9% (95% CI 92·4–95·2) in the neratinib group and 91·6% (90·0–93·0) in the placebo group. The most common grade 3–4 adverse events in patients in the neratinib group were diarrhoea (grade 3, n=561 [40%] and grade 4, n=1 [<1%] vs grade 3, n=23 [2%] in the placebo group), vomiting (grade 3, n=47 [3%] vs n=5 [<1%]), and nausea (grade 3, n=26 [2%] vs n=2 [<1%]). QT prolongation occurred in 49 (3%) patients given neratinib and 93 (7%) patients given placebo, and decreases in left ventricular ejection fraction (≥grade 2) in 19 (1%) and 15 (1%) patients, respectively. We recorded serious adverse events in 103 (7%) patients in the neratinib group and 85 (6%) patients in the placebo group. Seven (<1%) deaths (four patients in the neratinib group and three patients in the placebo group) unrelated to disease progression occurred after study drug discontinuation. The causes of death in the neratinib group were unknown (n=2), a second primary brain tumour (n=1), and acute myeloid leukaemia (n=1), and in the placebo group were a brain haemorrhage (n=1), myocardial infarction (n=1), and gastric cancer (n=1). None of the deaths were attributed to study treatment in either group.
Neratinib for 12 months significantly improved 2-year invasive disease-free survival when given after chemotherapy and trastuzumab-based adjuvant therapy to women with HER2-positive breast cancer. Longer follow-up is needed to ensure that the improvement in breast cancer outcome is maintained.
Wyeth, Pfizer, Puma Biotechnology. |
|---|---|
| AbstractList | SummaryBackgroundNeratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-positive breast cancer. MethodsWe did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 495 centres in Europe, Asia, Australia, New Zealand, and North and South America. Eligible women (aged ≥18 years, or ≥20 years in Japan) had stage 1–3 HER2-positive breast cancer and had completed neoadjuvant and adjuvant trastuzumab therapy up to 2 years before randomisation. Inclusion criteria were amended on Feb 25, 2010, to include patients with stage 2–3 HER2-positive breast cancer who had completed trastuzumab therapy up to 1 year previously. Patients were randomly assigned (1:1) to receive oral neratinib 240 mg per day or matching placebo. The randomisation sequence was generated with permuted blocks stratified by hormone receptor status (hormone receptor-positive [oestrogen or progesterone receptor-positive or both] vs hormone receptor-negative [oestrogen and progesterone receptor-negative]), nodal status (0, 1–3, or ≥4), and trastuzumab adjuvant regimen (sequentially vs concurrently with chemotherapy), then implemented centrally via an interactive voice and web-response system. Patients, investigators, and trial sponsors were masked to treatment allocation. The primary outcome was invasive disease-free survival, as defined in the original protocol, at 2 years after randomisation. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00878709. FindingsBetween July 9, 2009, and Oct 24, 2011, we randomly assigned 2840 women to receive neratinib (n=1420) or placebo (n=1420). Median follow-up time was 24 months (IQR 20–25) in the neratinib group and 24 months (22–25) in the placebo group. At 2 year follow-up, 70 invasive disease-free survival events had occurred in patients in the neratinib group versus 109 events in those in the placebo group (stratified hazard ratio 0·67, 95% CI 0·50–0·91; p=0·0091). The 2-year invasive disease-free survival rate was 93·9% (95% CI 92·4–95·2) in the neratinib group and 91·6% (90·0–93·0) in the placebo group. The most common grade 3–4 adverse events in patients in the neratinib group were diarrhoea (grade 3, n=561 [40%] and grade 4, n=1 [<1%] vs grade 3, n=23 [2%] in the placebo group), vomiting (grade 3, n=47 [3%] vs n=5 [<1%]), and nausea (grade 3, n=26 [2%] vs n=2 [<1%]). QT prolongation occurred in 49 (3%) patients given neratinib and 93 (7%) patients given placebo, and decreases in left ventricular ejection fraction (≥grade 2) in 19 (1%) and 15 (1%) patients, respectively. We recorded serious adverse events in 103 (7%) patients in the neratinib group and 85 (6%) patients in the placebo group. Seven (<1%) deaths (four patients in the neratinib group and three patients in the placebo group) unrelated to disease progression occurred after study drug discontinuation. The causes of death in the neratinib group were unknown (n=2), a second primary brain tumour (n=1), and acute myeloid leukaemia (n=1), and in the placebo group were a brain haemorrhage (n=1), myocardial infarction (n=1), and gastric cancer (n=1). None of the deaths were attributed to study treatment in either group. InterpretationNeratinib for 12 months significantly improved 2-year invasive disease-free survival when given after chemotherapy and trastuzumab-based adjuvant therapy to women with HER2-positive breast cancer. Longer follow-up is needed to ensure that the improvement in breast cancer outcome is maintained. FundingWyeth, Pfizer, Puma Biotechnology. Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-positive breast cancer. We did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 495 centres in Europe, Asia, Australia, New Zealand, and North and South America. Eligible women (aged ≥18 years, or ≥20 years in Japan) had stage 1-3 HER2-positive breast cancer and had completed neoadjuvant and adjuvant trastuzumab therapy up to 2 years before randomisation. Inclusion criteria were amended on Feb 25, 2010, to include patients with stage 2-3 HER2-positive breast cancer who had completed trastuzumab therapy up to 1 year previously. Patients were randomly assigned (1:1) to receive oral neratinib 240 mg per day or matching placebo. The randomisation sequence was generated with permuted blocks stratified by hormone receptor status (hormone receptor-positive [oestrogen or progesterone receptor-positive or both] vs hormone receptor-negative [oestrogen and progesterone receptor-negative]), nodal status (0, 1-3, or ≥4), and trastuzumab adjuvant regimen (sequentially vs concurrently with chemotherapy), then implemented centrally via an interactive voice and web-response system. Patients, investigators, and trial sponsors were masked to treatment allocation. The primary outcome was invasive disease-free survival, as defined in the original protocol, at 2 years after randomisation. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00878709. Between July 9, 2009, and Oct 24, 2011, we randomly assigned 2840 women to receive neratinib (n=1420) or placebo (n=1420). Median follow-up time was 24 months (IQR 20-25) in the neratinib group and 24 months (22-25) in the placebo group. At 2 year follow-up, 70 invasive disease-free survival events had occurred in patients in the neratinib group versus 109 events in those in the placebo group (stratified hazard ratio 0·67, 95% CI 0·50-0·91; p=0·0091). The 2-year invasive disease-free survival rate was 93·9% (95% CI 92·4-95·2) in the neratinib group and 91·6% (90·0-93·0) in the placebo group. The most common grade 3-4 adverse events in patients in the neratinib group were diarrhoea (grade 3, n=561 [40%] and grade 4, n=1 [<1%] vs grade 3, n=23 [2%] in the placebo group), vomiting (grade 3, n=47 [3%] vs n=5 [<1%]), and nausea (grade 3, n=26 [2%] vs n=2 [<1%]). QT prolongation occurred in 49 (3%) patients given neratinib and 93 (7%) patients given placebo, and decreases in left ventricular ejection fraction (≥grade 2) in 19 (1%) and 15 (1%) patients, respectively. We recorded serious adverse events in 103 (7%) patients in the neratinib group and 85 (6%) patients in the placebo group. Seven (<1%) deaths (four patients in the neratinib group and three patients in the placebo group) unrelated to disease progression occurred after study drug discontinuation. The causes of death in the neratinib group were unknown (n=2), a second primary brain tumour (n=1), and acute myeloid leukaemia (n=1), and in the placebo group were a brain haemorrhage (n=1), myocardial infarction (n=1), and gastric cancer (n=1). None of the deaths were attributed to study treatment in either group. Neratinib for 12 months significantly improved 2-year invasive disease-free survival when given after chemotherapy and trastuzumab-based adjuvant therapy to women with HER2-positive breast cancer. Longer follow-up is needed to ensure that the improvement in breast cancer outcome is maintained. Wyeth, Pfizer, Puma Biotechnology. Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-positive breast cancer. Methods We did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 495 centres in Europe, Asia, Australia, New Zealand, and North and South America. Eligible women (aged >=18 years, or >=20 years in Japan) had stage 1-3 HER2-positive breast cancer and had completed neoadjuvant and adjuvant trastuzumab therapy up to 2 years before randomisation. Inclusion criteria were amended on Feb 25, 2010, to include patients with stage 2-3 HER2-positive breast cancer who had completed trastuzumab therapy up to 1 year previously. Patients were randomly assigned (1:1) to receive oral neratinib 240 mg per day or matching placebo. The randomisation sequence was generated with permuted blocks stratified by hormone receptor status (hormone receptor-positive [oestrogen or progesterone receptor-positive or both]vshormone receptor-negative [oestrogen and progesterone receptor-negative]), nodal status (0, 1-3, or >=4), and trastuzumab adjuvant regimen (sequentiallyvsconcurrently with chemotherapy), then implemented centrally via an interactive voice and web-response system. Patients, investigators, and trial sponsors were masked to treatment allocation. The primary outcome was invasive disease-free survival, as defined in the original protocol, at 2 years after randomisation. Analysis was by intention to treat. This trial is registered withClinicalTrials.gov, numberNCT00878709. Findings Between July 9, 2009, and Oct 24, 2011, we randomly assigned 2840 women to receive neratinib (n=1420) or placebo (n=1420). Median follow-up time was 24 months (IQR 20-25) in the neratinib group and 24 months (22-25) in the placebo group. At 2 year follow-up, 70 invasive disease-free survival events had occurred in patients in the neratinib group versus 109 events in those in the placebo group (stratified hazard ratio 0·67, 95% CI 0·50-0·91; p=0·0091). The 2-year invasive disease-free survival rate was 93·9% (95% CI 92·4-95·2) in the neratinib group and 91·6% (90·0-93·0) in the placebo group. The most common grade 3-4 adverse events in patients in the neratinib group were diarrhoea (grade 3, n=561 [40%] and grade 4, n=1 [<1%]vsgrade 3, n=23 [2%] in the placebo group), vomiting (grade 3, n=47 [3%]vsn=5 [<1%]), and nausea (grade 3, n=26 [2%]vsn=2 [<1%]). QT prolongation occurred in 49 (3%) patients given neratinib and 93 (7%) patients given placebo, and decreases in left ventricular ejection fraction (>=grade 2) in 19 (1%) and 15 (1%) patients, respectively. We recorded serious adverse events in 103 (7%) patients in the neratinib group and 85 (6%) patients in the placebo group. Seven (<1%) deaths (four patients in the neratinib group and three patients in the placebo group) unrelated to disease progression occurred after study drug discontinuation. The causes of death in the neratinib group were unknown (n=2), a second primary brain tumour (n=1), and acute myeloid leukaemia (n=1), and in the placebo group were a brain haemorrhage (n=1), myocardial infarction (n=1), and gastric cancer (n=1). None of the deaths were attributed to study treatment in either group. Interpretation Neratinib for 12 months significantly improved 2-year invasive disease-free survival when given after chemotherapy and trastuzumab-based adjuvant therapy to women with HER2-positive breast cancer. Longer follow-up is needed to ensure that the improvement in breast cancer outcome is maintained. Funding Wyeth, Pfizer, Puma Biotechnology. Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-positive breast cancer.BACKGROUNDNeratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with early-stage HER2-positive breast cancer.We did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 495 centres in Europe, Asia, Australia, New Zealand, and North and South America. Eligible women (aged ≥18 years, or ≥20 years in Japan) had stage 1-3 HER2-positive breast cancer and had completed neoadjuvant and adjuvant trastuzumab therapy up to 2 years before randomisation. Inclusion criteria were amended on Feb 25, 2010, to include patients with stage 2-3 HER2-positive breast cancer who had completed trastuzumab therapy up to 1 year previously. Patients were randomly assigned (1:1) to receive oral neratinib 240 mg per day or matching placebo. The randomisation sequence was generated with permuted blocks stratified by hormone receptor status (hormone receptor-positive [oestrogen or progesterone receptor-positive or both] vs hormone receptor-negative [oestrogen and progesterone receptor-negative]), nodal status (0, 1-3, or ≥4), and trastuzumab adjuvant regimen (sequentially vs concurrently with chemotherapy), then implemented centrally via an interactive voice and web-response system. Patients, investigators, and trial sponsors were masked to treatment allocation. The primary outcome was invasive disease-free survival, as defined in the original protocol, at 2 years after randomisation. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00878709.METHODSWe did this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 495 centres in Europe, Asia, Australia, New Zealand, and North and South America. Eligible women (aged ≥18 years, or ≥20 years in Japan) had stage 1-3 HER2-positive breast cancer and had completed neoadjuvant and adjuvant trastuzumab therapy up to 2 years before randomisation. Inclusion criteria were amended on Feb 25, 2010, to include patients with stage 2-3 HER2-positive breast cancer who had completed trastuzumab therapy up to 1 year previously. Patients were randomly assigned (1:1) to receive oral neratinib 240 mg per day or matching placebo. The randomisation sequence was generated with permuted blocks stratified by hormone receptor status (hormone receptor-positive [oestrogen or progesterone receptor-positive or both] vs hormone receptor-negative [oestrogen and progesterone receptor-negative]), nodal status (0, 1-3, or ≥4), and trastuzumab adjuvant regimen (sequentially vs concurrently with chemotherapy), then implemented centrally via an interactive voice and web-response system. Patients, investigators, and trial sponsors were masked to treatment allocation. The primary outcome was invasive disease-free survival, as defined in the original protocol, at 2 years after randomisation. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00878709.Between July 9, 2009, and Oct 24, 2011, we randomly assigned 2840 women to receive neratinib (n=1420) or placebo (n=1420). Median follow-up time was 24 months (IQR 20-25) in the neratinib group and 24 months (22-25) in the placebo group. At 2 year follow-up, 70 invasive disease-free survival events had occurred in patients in the neratinib group versus 109 events in those in the placebo group (stratified hazard ratio 0·67, 95% CI 0·50-0·91; p=0·0091). The 2-year invasive disease-free survival rate was 93·9% (95% CI 92·4-95·2) in the neratinib group and 91·6% (90·0-93·0) in the placebo group. The most common grade 3-4 adverse events in patients in the neratinib group were diarrhoea (grade 3, n=561 [40%] and grade 4, n=1 [<1%] vs grade 3, n=23 [2%] in the placebo group), vomiting (grade 3, n=47 [3%] vs n=5 [<1%]), and nausea (grade 3, n=26 [2%] vs n=2 [<1%]). QT prolongation occurred in 49 (3%) patients given neratinib and 93 (7%) patients given placebo, and decreases in left ventricular ejection fraction (≥grade 2) in 19 (1%) and 15 (1%) patients, respectively. We recorded serious adverse events in 103 (7%) patients in the neratinib group and 85 (6%) patients in the placebo group. Seven (<1%) deaths (four patients in the neratinib group and three patients in the placebo group) unrelated to disease progression occurred after study drug discontinuation. The causes of death in the neratinib group were unknown (n=2), a second primary brain tumour (n=1), and acute myeloid leukaemia (n=1), and in the placebo group were a brain haemorrhage (n=1), myocardial infarction (n=1), and gastric cancer (n=1). None of the deaths were attributed to study treatment in either group.FINDINGSBetween July 9, 2009, and Oct 24, 2011, we randomly assigned 2840 women to receive neratinib (n=1420) or placebo (n=1420). Median follow-up time was 24 months (IQR 20-25) in the neratinib group and 24 months (22-25) in the placebo group. At 2 year follow-up, 70 invasive disease-free survival events had occurred in patients in the neratinib group versus 109 events in those in the placebo group (stratified hazard ratio 0·67, 95% CI 0·50-0·91; p=0·0091). The 2-year invasive disease-free survival rate was 93·9% (95% CI 92·4-95·2) in the neratinib group and 91·6% (90·0-93·0) in the placebo group. The most common grade 3-4 adverse events in patients in the neratinib group were diarrhoea (grade 3, n=561 [40%] and grade 4, n=1 [<1%] vs grade 3, n=23 [2%] in the placebo group), vomiting (grade 3, n=47 [3%] vs n=5 [<1%]), and nausea (grade 3, n=26 [2%] vs n=2 [<1%]). QT prolongation occurred in 49 (3%) patients given neratinib and 93 (7%) patients given placebo, and decreases in left ventricular ejection fraction (≥grade 2) in 19 (1%) and 15 (1%) patients, respectively. We recorded serious adverse events in 103 (7%) patients in the neratinib group and 85 (6%) patients in the placebo group. Seven (<1%) deaths (four patients in the neratinib group and three patients in the placebo group) unrelated to disease progression occurred after study drug discontinuation. The causes of death in the neratinib group were unknown (n=2), a second primary brain tumour (n=1), and acute myeloid leukaemia (n=1), and in the placebo group were a brain haemorrhage (n=1), myocardial infarction (n=1), and gastric cancer (n=1). None of the deaths were attributed to study treatment in either group.Neratinib for 12 months significantly improved 2-year invasive disease-free survival when given after chemotherapy and trastuzumab-based adjuvant therapy to women with HER2-positive breast cancer. Longer follow-up is needed to ensure that the improvement in breast cancer outcome is maintained.INTERPRETATIONNeratinib for 12 months significantly improved 2-year invasive disease-free survival when given after chemotherapy and trastuzumab-based adjuvant therapy to women with HER2-positive breast cancer. Longer follow-up is needed to ensure that the improvement in breast cancer outcome is maintained.Wyeth, Pfizer, Puma Biotechnology.FUNDINGWyeth, Pfizer, Puma Biotechnology. |
| Author | Iannotti, Nicholas Rodriguez, Gladys Masuda, Norikazu Buyse, Marc Smith, John Gore, Ira Mansi, Janine Ejlertsen, Bent Barrios, Carlos H Martin, Miguel Silovski, Tajana Ye, Yining Tassone, Pierfrancesco Delaloge, Suzette Chia, Stephen K L Chan, Arlene Holmes, Frankie A Yao, Bin Gokmen, Erhan Harvey, Vernon J Robert, Nicholas J Zotano, Angel Guerrero Wong, Alvin Harker, Graydon Iwata, Hiroji von Minckwitz, Gunter Petrakova, Katarina Gnant, Michael Moy, Beverly Bryce, Richard |
| Author_xml | – sequence: 1 givenname: Arlene surname: Chan fullname: Chan, Arlene email: arlenechan@me.com organization: Breast Cancer Research Centre-Western Australia and Curtin University, Perth, WA, Australia – sequence: 2 givenname: Suzette surname: Delaloge fullname: Delaloge, Suzette organization: Institut Gustave Roussy, Villejuif, France – sequence: 3 givenname: Frankie A surname: Holmes fullname: Holmes, Frankie A organization: Texas Oncology, Houston, TX, USA – sequence: 4 givenname: Beverly surname: Moy fullname: Moy, Beverly organization: Massachusetts General Hospital Cancer Center, Boston, MA, USA – sequence: 5 givenname: Hiroji surname: Iwata fullname: Iwata, Hiroji organization: Aichi Cancer Center, Chikusa-ku, Nagoya, Japan – sequence: 6 givenname: Vernon J surname: Harvey fullname: Harvey, Vernon J organization: Auckland Hospital, Auckland, New Zealand – sequence: 7 givenname: Nicholas J surname: Robert fullname: Robert, Nicholas J organization: Virginia Cancer Specialists, The US Oncology Network, Fairfax, VA, USA – sequence: 8 givenname: Tajana surname: Silovski fullname: Silovski, Tajana organization: University Hospital For Tumors, University Hospital Center “Sestre Milosrdnice”, Zagreb, Croatia – sequence: 9 givenname: Erhan surname: Gokmen fullname: Gokmen, Erhan organization: Ege University Faculty of Medicine, Izmir, Turkey – sequence: 10 givenname: Gunter surname: von Minckwitz fullname: von Minckwitz, Gunter organization: Luisenkrankenhaus, German Breast Group Forschungs GmbH, Düsseldorf, Neu-lsenburg, Germany – sequence: 11 givenname: Bent surname: Ejlertsen fullname: Ejlertsen, Bent organization: Rigshospitalet, Copenhagen, Denmark – sequence: 12 givenname: Stephen K L surname: Chia fullname: Chia, Stephen K L organization: BC Cancer Agency, Vancouver, BC, Canada – sequence: 13 givenname: Janine surname: Mansi fullname: Mansi, Janine organization: Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, UK – sequence: 14 givenname: Carlos H surname: Barrios fullname: Barrios, Carlos H organization: Pontifical Catholic University of Rio Grande do Sul School of Medicine, Porto Alegre, Brazil – sequence: 15 givenname: Michael surname: Gnant fullname: Gnant, Michael organization: Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria – sequence: 16 givenname: Marc surname: Buyse fullname: Buyse, Marc organization: International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium – sequence: 17 givenname: Ira surname: Gore fullname: Gore, Ira organization: Alabama Oncology, Birmingham, AL, USA – sequence: 18 givenname: John surname: Smith fullname: Smith, John organization: Northwest Cancer Specialists, Vancouver, VA, USA – sequence: 19 givenname: Graydon surname: Harker fullname: Harker, Graydon organization: Utah Cancer Specialists, Salt Lake City, UT, USA – sequence: 20 givenname: Norikazu surname: Masuda fullname: Masuda, Norikazu organization: National Hospital Organization Osaka National Hospital, Chuou-ku, Osaka, Japan – sequence: 21 givenname: Katarina surname: Petrakova fullname: Petrakova, Katarina organization: Masaryk Memorial Cancer Institute, Brno, Czech Republic – sequence: 22 givenname: Angel Guerrero surname: Zotano fullname: Zotano, Angel Guerrero organization: Instituto Valenciano de Oncologia, València, Spain – sequence: 23 givenname: Nicholas surname: Iannotti fullname: Iannotti, Nicholas organization: Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, FL, USA – sequence: 24 givenname: Gladys surname: Rodriguez fullname: Rodriguez, Gladys organization: South Texas Oncology and Hematology, San Antonio, TX, USA – sequence: 25 givenname: Pierfrancesco surname: Tassone fullname: Tassone, Pierfrancesco organization: Magna Graecia University, Catanzaro, Italy – sequence: 26 givenname: Alvin surname: Wong fullname: Wong, Alvin organization: Puma Biotechnology, Los Angeles, CA, USA – sequence: 27 givenname: Richard surname: Bryce fullname: Bryce, Richard organization: Puma Biotechnology, Los Angeles, CA, USA – sequence: 28 givenname: Yining surname: Ye fullname: Ye, Yining organization: Puma Biotechnology, Los Angeles, CA, USA – sequence: 29 givenname: Bin surname: Yao fullname: Yao, Bin organization: Puma Biotechnology, Los Angeles, CA, USA – sequence: 30 givenname: Miguel surname: Martin fullname: Martin, Miguel organization: Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26874901$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkV2L1DAUhousuB_6E5SAN7Ow1SRNmnZFRZbRFZYVdL0OaXqGyZhpapKOjv_L_2c63UUYkPUqTXneJ4fzHmcHnesgy54S_IJgUr78QpjAOcWMzwg_xZhzkhcPsqP0m-WcVdXB7ntCDrPjEFYYE0Ewf5Qd0rISrMbkKPt9DV5F05kGqUUEj6JXIQ6_hrVq8kYFaJFqV8NGdRHFZWL7LTId6lMGuhjQDxOX6HL-mea9CyaaDaDGQ1IgrTqdfLP5zwjX85vTc6TQerDR6BT0cIa86lq3NumJM9S6obGQN9Z06dZbpaFxuXaJdNaORL9Mw6AizWeUfZw9XCgb4MnteZJ9fT-_ubjMrz59-Hjx7irXHNOYVxVrSkE1EMAc2IKxulY1JW2hWEmhrRkt2kqAYJQyIeq24FpgxTiFlKxIcZLNJm_v3fcBQpRpXg3Wqg7cECQRomCUlaJM6PM9dOUG36XpRopQUlZ1lahnt9TQrKGVvTdr5bfyrpAEvJoA7V0IHhZSm5iWPW5CGSsJlmP9cle_HLuVhMtd_bJIab6XvnvgvtzbKQdpmRsDXgad-tXQGg86ytaZew1v9gw6dWm0st9gC-HvLmSgEk-S0UH4zjAKXv9b8B8D_AEUQ-78 |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1007_s12609_017_0239_6 crossref_primary_10_1007_s11912_022_01215_1 crossref_primary_10_1093_annonc_mdx308 crossref_primary_10_1016_j_ctrv_2024_102769 crossref_primary_10_1055_a_2143_8125 crossref_primary_10_1111_bcp_13132 crossref_primary_10_1002_ange_201803394 crossref_primary_10_3390_jpm11080808 crossref_primary_10_1186_s12885_020_07546_1 crossref_primary_10_1016_j_asjsur_2023_03_132 crossref_primary_10_2147_CIA_S365497 crossref_primary_10_1007_s12094_018_1973_6 crossref_primary_10_1016_j_ejca_2022_06_012 crossref_primary_10_1038_s41379_020_00695_5 crossref_primary_10_3390_cancers12061573 crossref_primary_10_2147_CMAR_S486211 crossref_primary_10_1038_s41389_024_00531_4 crossref_primary_10_1091_mbc_E18_07_0460 crossref_primary_10_1097_CCO_0000000000000325 crossref_primary_10_1016_j_jgo_2021_02_020 crossref_primary_10_1016_S1470_2045_16_30018_3 crossref_primary_10_2147_BCTT_S288344 crossref_primary_10_1002_cncr_33102 crossref_primary_10_3390_cancers13051052 crossref_primary_10_1200_EDBK_280807 crossref_primary_10_1002_pst_1835 crossref_primary_10_1038_nrclinonc_2017_96 crossref_primary_10_3390_cancers12092634 crossref_primary_10_1007_s12254_019_00543_6 crossref_primary_10_1089_ars_2017_7155 crossref_primary_10_3390_vaccines12070808 crossref_primary_10_1016_j_intimp_2024_111549 crossref_primary_10_1016_j_annonc_2023_08_005 crossref_primary_10_1186_s13000_021_01187_z crossref_primary_10_1093_annonc_mdz039 crossref_primary_10_1158_1078_0432_CCR_17_3351 crossref_primary_10_1038_s41571_018_0030_2 crossref_primary_10_1007_s40261_018_0741_2 crossref_primary_10_1080_0284186X_2017_1408962 crossref_primary_10_1007_s12094_024_03472_x crossref_primary_10_1016_j_clbc_2018_09_010 crossref_primary_10_1093_toxres_tfab026 crossref_primary_10_1177_17588359221106564 crossref_primary_10_3390_cancers13205198 crossref_primary_10_1016_j_bcp_2022_115209 crossref_primary_10_1016_S1470_2045_18_30256_0 crossref_primary_10_1080_14737140_2020_1829484 crossref_primary_10_1016_j_canlet_2022_216024 crossref_primary_10_1007_s10549_021_06427_w crossref_primary_10_1038_s41416_024_02665_z crossref_primary_10_1007_s40265_017_0774_5 crossref_primary_10_1016_j_critrevonc_2018_03_010 crossref_primary_10_1038_s41571_019_0299_9 crossref_primary_10_1200_EDBK_175630 crossref_primary_10_1007_s10549_018_05102_x crossref_primary_10_1002_cam4_3095 crossref_primary_10_1007_s12609_018_0290_y crossref_primary_10_3389_fonc_2018_00089 crossref_primary_10_1016_j_critrevonc_2017_10_001 crossref_primary_10_1177_1073274819870549 crossref_primary_10_2217_fon_2018_0896 crossref_primary_10_1007_s40487_018_0090_6 crossref_primary_10_1016_j_breast_2017_10_014 crossref_primary_10_1053_j_seminoncol_2020_07_007 crossref_primary_10_1186_s12885_021_08894_2 crossref_primary_10_1093_jnci_djx179 crossref_primary_10_1016_j_ygyno_2025_03_011 crossref_primary_10_1016_j_ygyno_2022_05_021 crossref_primary_10_1007_s11936_024_01067_x crossref_primary_10_36290_xon_2017_035 crossref_primary_10_1016_j_breast_2018_03_006 crossref_primary_10_1007_s12032_022_01749_1 crossref_primary_10_1007_s12094_024_03409_4 crossref_primary_10_1016_j_currproblcancer_2016_09_002 crossref_primary_10_1080_14656566_2016_1244528 crossref_primary_10_3892_etm_2021_11037 crossref_primary_10_1016_j_currproblcancer_2016_09_005 crossref_primary_10_1158_1078_0432_CCR_16_2191 crossref_primary_10_1080_17425255_2023_2244870 crossref_primary_10_1016_j_clbc_2025_05_009 crossref_primary_10_1038_s41392_019_0069_2 crossref_primary_10_1200_EDBK_280463 crossref_primary_10_1002_cnr2_70065 crossref_primary_10_1016_j_breast_2016_07_026 crossref_primary_10_3390_cancers17172769 crossref_primary_10_1177_17588359231220501 crossref_primary_10_2217_fon_2018_0402 crossref_primary_10_2217_fon_2019_0222 crossref_primary_10_1515_cclm_2017_0592 crossref_primary_10_3390_cancers15092568 crossref_primary_10_1186_s10020_023_00736_0 crossref_primary_10_1200_JCO_2018_78_8604 crossref_primary_10_3389_fendo_2022_830097 crossref_primary_10_1016_j_clbc_2021_05_012 crossref_primary_10_1016_j_breast_2024_103713 crossref_primary_10_3390_jpm13020365 crossref_primary_10_1200_JCO_19_00083 crossref_primary_10_1007_s10549_017_4397_z crossref_primary_10_1002_prp2_521 crossref_primary_10_1007_s10555_018_9761_x crossref_primary_10_1016_j_clbc_2021_02_001 crossref_primary_10_1080_14740338_2017_1351541 crossref_primary_10_1038_s41571_018_0089_9 crossref_primary_10_1515_cclm_2019_0376 crossref_primary_10_1200_EDBK_281381 crossref_primary_10_3892_etm_2018_6459 crossref_primary_10_1038_s41598_018_33682_7 crossref_primary_10_1038_s41419_021_03457_6 crossref_primary_10_3390_ijms242316823 crossref_primary_10_1111_jcmm_17210 crossref_primary_10_1200_JCO_18_01511 crossref_primary_10_1159_000518696 crossref_primary_10_1080_07357907_2019_1634089 crossref_primary_10_3389_fonc_2018_00227 crossref_primary_10_1038_s41523_022_00430_0 crossref_primary_10_14423_SMJ_0000000000000709 crossref_primary_10_1016_j_neo_2022_100806 crossref_primary_10_3390_cancers13225771 crossref_primary_10_1002_jcp_25427 crossref_primary_10_1016_j_jgo_2019_05_012 crossref_primary_10_1634_theoncologist_2017_0079 crossref_primary_10_3390_jcm13071873 crossref_primary_10_1016_S1470_2045_18_30812_X crossref_primary_10_1158_1078_0432_CCR_17_3431 crossref_primary_10_36290_xon_2023_030 crossref_primary_10_7554_eLife_101724_3 crossref_primary_10_1097_CCO_0000000000000412 crossref_primary_10_1038_s41598_020_72944_1 crossref_primary_10_1007_s11864_023_01070_7 crossref_primary_10_1016_j_cellsig_2025_112108 crossref_primary_10_3390_molecules29071448 crossref_primary_10_1016_j_ejca_2018_07_134 crossref_primary_10_3390_cimb47100789 crossref_primary_10_1016_j_ygyno_2020_07_025 crossref_primary_10_3390_ijms25020732 crossref_primary_10_1016_j_breast_2018_10_008 crossref_primary_10_15252_emmm_201911498 crossref_primary_10_1055_s_0041_1731861 crossref_primary_10_1007_s10741_020_10072_8 crossref_primary_10_1016_j_clbc_2018_12_011 crossref_primary_10_1016_j_ctrv_2021_102229 crossref_primary_10_1002_onco_13830 crossref_primary_10_1016_j_suc_2022_08_017 crossref_primary_10_1002_ijc_32859 crossref_primary_10_1097_CCO_0000000000000984 crossref_primary_10_1186_s12967_017_1239_z crossref_primary_10_1016_j_biopha_2020_110361 crossref_primary_10_3390_jcm12041336 crossref_primary_10_1080_14737140_2021_1996229 crossref_primary_10_1007_s00129_017_4085_4 crossref_primary_10_1007_s00280_018_3756_8 crossref_primary_10_1016_j_ctrv_2017_10_005 crossref_primary_10_1038_s41523_021_00265_1 crossref_primary_10_1038_s43018_020_0067_x crossref_primary_10_1016_j_bcp_2023_115633 crossref_primary_10_1016_S0140_6736_16_32616_2 crossref_primary_10_2217_fon_2017_0186 crossref_primary_10_3389_fcvm_2023_1078135 crossref_primary_10_1177_10781552221119797 crossref_primary_10_1007_s12254_023_00942_w crossref_primary_10_1016_j_breast_2022_12_003 crossref_primary_10_1177_1534735420928493 crossref_primary_10_1039_D4SC05459H crossref_primary_10_1177_1533033820962140 crossref_primary_10_1002_ijc_31651 crossref_primary_10_3390_cancers14143305 crossref_primary_10_1007_s40266_018_0519_5 crossref_primary_10_3389_fonc_2023_1221969 crossref_primary_10_1158_1078_0432_CCR_18_1131 crossref_primary_10_2217_fon_2019_0143 crossref_primary_10_1097_HCO_0000000000000637 crossref_primary_10_2217_fon_2023_0361 crossref_primary_10_1016_j_clbc_2020_09_014 crossref_primary_10_1371_journal_pone_0282769 crossref_primary_10_1159_000513800 crossref_primary_10_1016_j_omto_2023_02_006 crossref_primary_10_1016_S0007_4551_23_00473_3 crossref_primary_10_1002_mco2_181 crossref_primary_10_1177_1060028018824088 crossref_primary_10_1016_j_path_2021_05_009 crossref_primary_10_1111_cas_13546 crossref_primary_10_14814_phy2_70008 crossref_primary_10_1158_1078_0432_CCR_17_0900 crossref_primary_10_4137_CMT_S18492 crossref_primary_10_3389_fonc_2018_00144 crossref_primary_10_1007_s12609_019_00347_x crossref_primary_10_1200_JCO_2017_75_9175 crossref_primary_10_1038_s41573_022_00579_0 crossref_primary_10_1080_14737140_2017_1338954 crossref_primary_10_1007_s11095_020_02851_7 crossref_primary_10_1016_j_ejca_2023_02_002 crossref_primary_10_1080_1120009X_2018_1516269 crossref_primary_10_1016_j_drup_2025_101288 crossref_primary_10_1186_s13046_019_1094_2 crossref_primary_10_3390_cancers14102424 crossref_primary_10_1016_j_ejca_2021_03_045 crossref_primary_10_1016_j_compbiolchem_2018_04_002 crossref_primary_10_1155_2020_5169278 crossref_primary_10_1016_j_ejca_2021_06_026 crossref_primary_10_2217_fon_2020_0504 crossref_primary_10_1038_s41571_019_0268_3 crossref_primary_10_1007_s10549_019_05303_y crossref_primary_10_1007_s40261_018_0719_0 crossref_primary_10_1200_JCO_19_00858 crossref_primary_10_3389_fonc_2024_1484750 crossref_primary_10_1007_s00428_023_03640_4 crossref_primary_10_1007_s15015_016_2867_5 crossref_primary_10_1080_13543784_2018_1520838 crossref_primary_10_3390_pharmaceutics13050723 crossref_primary_10_1007_s10549_018_4959_8 crossref_primary_10_1016_j_coph_2016_11_005 crossref_primary_10_1016_j_ctrv_2019_101944 crossref_primary_10_1111_ajco_13655 crossref_primary_10_1159_000479499 crossref_primary_10_1016_S1470_2045_16_00165_0 crossref_primary_10_1177_1179554920931816 crossref_primary_10_1016_S1470_2045_19_30338_9 crossref_primary_10_1007_s10637_018_0649_y crossref_primary_10_2217_cns_2016_0038 crossref_primary_10_1001_jamanetworkopen_2020_0363 crossref_primary_10_1080_17425255_2016_1198317 crossref_primary_10_1016_S0140_6736_17_30322_7 crossref_primary_10_2174_0115733947282469240212075845 crossref_primary_10_3390_pharmaceutics12060524 crossref_primary_10_7554_eLife_101724 crossref_primary_10_1007_s10549_021_06280_x crossref_primary_10_1002_ijc_32418 crossref_primary_10_3390_cancers14184543 crossref_primary_10_1016_j_ejca_2017_10_037 crossref_primary_10_1186_s13058_019_1112_5 crossref_primary_10_3390_cancers15020554 crossref_primary_10_1002_anie_201803394 crossref_primary_10_3389_fonc_2020_575978 crossref_primary_10_1007_s11864_021_00879_4 crossref_primary_10_1016_j_bpobgyn_2022_02_004 crossref_primary_10_1016_j_bcp_2016_11_004 crossref_primary_10_1007_s40487_021_00178_w crossref_primary_10_1007_s41974_024_00340_y crossref_primary_10_1016_j_ctrv_2018_05_004 crossref_primary_10_1056_NEJMe1603691 crossref_primary_10_1007_s10549_021_06313_5 crossref_primary_10_1007_s40487_021_00153_5 crossref_primary_10_3390_jcm14155267 crossref_primary_10_1016_j_annonc_2020_05_012 crossref_primary_10_1016_j_ejca_2024_114227 crossref_primary_10_1038_s41420_020_00337_4 crossref_primary_10_3390_polym15163380 crossref_primary_10_1016_j_clbc_2023_06_014 crossref_primary_10_1080_14737140_2019_1613892 crossref_primary_10_1007_s00280_019_03951_x crossref_primary_10_1177_10732748241278039 crossref_primary_10_1007_s12609_020_00396_7 crossref_primary_10_7759_cureus_55230 crossref_primary_10_1111_tbj_13966 crossref_primary_10_1055_s_0041_1729726 crossref_primary_10_1002_jso_27523 crossref_primary_10_1016_S1470_2045_17_30717_9 crossref_primary_10_1016_j_tcm_2018_06_001 crossref_primary_10_3389_fonc_2019_01453 crossref_primary_10_3390_cancers15174336 crossref_primary_10_1016_j_canlet_2019_11_026 crossref_primary_10_1080_14737140_2019_1660164 crossref_primary_10_3390_cancers15051413 crossref_primary_10_3390_medsci10020027 crossref_primary_10_1007_s10549_022_06703_3 crossref_primary_10_1080_17425255_2017_1398733 crossref_primary_10_1080_14737140_2017_1264876 crossref_primary_10_1155_2017_7849108 crossref_primary_10_1038_s41523_023_00533_2 crossref_primary_10_2217_fon_2020_0046 crossref_primary_10_1016_j_breast_2020_10_003 crossref_primary_10_1136_postgradmedj_2018_135739 crossref_primary_10_1007_s11523_021_00838_x crossref_primary_10_3390_cancers16132466 crossref_primary_10_2340_actadv_v104_40555 crossref_primary_10_1080_14737140_2018_1477596 crossref_primary_10_1016_j_ejca_2021_04_044 crossref_primary_10_1007_s00520_021_06016_z crossref_primary_10_1080_09546634_2018_1536253 crossref_primary_10_1186_s13058_019_1115_2 crossref_primary_10_1093_toxres_tfab111 crossref_primary_10_1200_EDBK_159167 crossref_primary_10_1186_s12943_024_02035_6 crossref_primary_10_1097_CCO_0000000000000492 crossref_primary_10_1186_s40164_019_0149_6 crossref_primary_10_3390_ijms23126547 crossref_primary_10_3389_fphar_2021_741451 crossref_primary_10_1002_mc_22963 crossref_primary_10_1016_j_tranon_2024_102073 crossref_primary_10_1093_annonc_mdz016 crossref_primary_10_1016_j_cll_2023_08_001 crossref_primary_10_2217_fon_2020_0036 crossref_primary_10_1200_EDBK_100023 crossref_primary_10_1038_s41467_019_12880_5 crossref_primary_10_1002_onco_13546 crossref_primary_10_1002_jcph_1382 crossref_primary_10_1080_14737140_2022_2063844 crossref_primary_10_1158_2159_8290_CD_20_0215 crossref_primary_10_12688_f1000research_9619_1 crossref_primary_10_3390_cancers14163996 crossref_primary_10_18553_jmcp_2025_31_9_929 crossref_primary_10_3390_cancers14051246 crossref_primary_10_1016_j_eclinm_2025_103311 crossref_primary_10_1016_j_heliyon_2024_e27531 crossref_primary_10_3390_cancers15071987 crossref_primary_10_1016_S0140_6736_16_32417_5 crossref_primary_10_1007_s12032_017_0956_8 crossref_primary_10_1080_01480545_2021_1957556 crossref_primary_10_1016_j_ejps_2020_105401 crossref_primary_10_1177_1758835918775697 crossref_primary_10_1007_s40265_017_0811_4 crossref_primary_10_1080_14740338_2025_2489529 crossref_primary_10_1016_j_canlet_2020_07_029 crossref_primary_10_1177_1758835919887665 crossref_primary_10_1158_1078_0432_CCR_21_3177 crossref_primary_10_1016_j_ctrv_2016_11_002 crossref_primary_10_1016_j_tranon_2020_100862 crossref_primary_10_1080_14756366_2019_1634704 crossref_primary_10_3390_cancers13122922 crossref_primary_10_1055_a_1464_0953 crossref_primary_10_3390_cancers15153847 crossref_primary_10_1158_1078_0432_CCR_21_1317 crossref_primary_10_1158_2159_8290_CD_16_1431 crossref_primary_10_1016_j_jgo_2019_06_004 crossref_primary_10_1080_17512433_2019_1552134 crossref_primary_10_1080_17425255_2021_2004116 crossref_primary_10_1080_14740338_2017_1354986 crossref_primary_10_3390_cancers12113317 crossref_primary_10_1200_OP_21_00159 crossref_primary_10_3322_caac_21634 crossref_primary_10_1016_S0140_6736_19_30946_8 crossref_primary_10_1080_14737140_2016_1247698 crossref_primary_10_1186_s13578_020_00415_1 crossref_primary_10_1200_JCO_19_01681 crossref_primary_10_1007_s10549_020_05891_0 crossref_primary_10_1158_1078_0432_CCR_18_2867 crossref_primary_10_3390_biom9100629 crossref_primary_10_1186_s12885_022_09346_1 crossref_primary_10_1007_s10549_023_07038_3 crossref_primary_10_1007_s11912_021_01114_x crossref_primary_10_1080_13543784_2019_1633306 crossref_primary_10_1016_S1470_2045_17_30844_6 crossref_primary_10_1080_14737167_2024_2352006 crossref_primary_10_3389_fonc_2018_00177 crossref_primary_10_1016_j_clbc_2016_05_016 crossref_primary_10_1016_j_ctrv_2018_10_014 crossref_primary_10_3389_fphar_2023_1244597 crossref_primary_10_1177_1178223420935871 crossref_primary_10_3390_jcm12144646 crossref_primary_10_1200_JCO_18_00131 crossref_primary_10_1038_s41392_025_02181_3 crossref_primary_10_1016_j_pharmthera_2020_107677 crossref_primary_10_1177_1758834016656494 |
| Cites_doi | 10.1186/bcr1612 10.1016/S1470-2045(11)70033-X 10.1056/NEJMoa0910383 10.1200/JCO.2009.25.8707 10.1016/S1470-2045(14)70320-1 10.1016/S1470-2045(14)70006-3 10.1158/1078-0432.CCR-04-2569 10.1200/JCO.2008.21.4437 10.1158/0008-5472.CAN-07-3293 10.1007/s00280-013-2262-2 10.1126/science.3798106 10.1200/JCO.2008.21.4577 10.1093/annonc/mdu438.47 10.1007/s10549-012-2067-8 10.1200/JCO.2011.36.7045 10.1016/S0140-6736(09)61964-4 10.1016/S1470-2045(11)70336-9 10.1016/j.jclinepi.2004.01.012 10.1093/annonc/mdn005 10.1200/JCO.2014.55.5730 10.1056/NEJMoa052306 10.1056/NEJMoa052122 10.1158/1078-0432.CCR-08-1978 10.1186/1477-7525-5-70 10.1200/JCO.2008.19.6618 10.1158/1078-0432.CCR-05-0354 10.1001/jamaoncol.2016.0237 10.1016/j.ejca.2013.07.142 10.1016/0197-2456(86)90034-6 10.1016/S0140-6736(13)61094-6 10.18632/oncotarget.1148 10.1038/ncponc0558 10.1186/bcr3067 10.1016/S1470-2045(13)70017-2 |
| ContentType | Journal Article |
| Copyright | 2016 Elsevier Ltd Elsevier Ltd Copyright © 2016 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Mar 2016 |
| Copyright_xml | – notice: 2016 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2016 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Mar 2016 |
| CorporateAuthor | ExteNET Study Group |
| CorporateAuthor_xml | – name: ExteNET Study Group |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 |
| DOI | 10.1016/S1470-2045(15)00551-3 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & allied health premium. Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database (subscription) Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Oncogenes and Growth Factors Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & allied health premium. url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | 377 |
| ExternalDocumentID | 3973690041 26874901 10_1016_S1470_2045_15_00551_3 S1470204515005513 1_s2_0_S1470204515005513 |
| Genre | Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation | Wyeth, Pfizer, Puma Biotechnology. |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R ~HD 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF ABLVK ABYKQ AHPSJ AJBFU ZA5 9DU AAYXX AFFHD CITATION CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI 7X8 |
| ID | FETCH-LOGICAL-c502t-884b672ce1e05e4f4499a921d3a462ed9423d87e74224779d35c70a452e84b813 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 452 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000371234900049&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Sun Nov 09 12:31:22 EST 2025 Tue Oct 07 05:29:04 EDT 2025 Wed Feb 19 02:30:43 EST 2025 Sat Nov 29 07:02:29 EST 2025 Tue Nov 18 22:20:14 EST 2025 Fri Feb 23 02:48:58 EST 2024 Tue Feb 25 20:02:55 EST 2025 Tue Oct 14 19:38:59 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | Copyright © 2016 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c502t-884b672ce1e05e4f4499a921d3a462ed9423d87e74224779d35c70a452e84b813 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| PMID | 26874901 |
| PQID | 1771216898 |
| PQPubID | 46089 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_1773424676 proquest_journals_1771216898 pubmed_primary_26874901 crossref_citationtrail_10_1016_S1470_2045_15_00551_3 crossref_primary_10_1016_S1470_2045_15_00551_3 elsevier_sciencedirect_doi_10_1016_S1470_2045_15_00551_3 elsevier_clinicalkeyesjournals_1_s2_0_S1470204515005513 elsevier_clinicalkey_doi_10_1016_S1470_2045_15_00551_3 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-03-01 |
| PublicationDateYYYYMMDD | 2016-03-01 |
| PublicationDate_xml | – month: 03 year: 2016 text: 2016-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2016 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | De Laurentiis, Arpino, Massarelli (bib23) 2005; 11 Joensuu, Bono, Kataja (bib6) 2009; 27 von Minckwitz, du Bois, Schmidt (bib15) 2009; 27 Andreyev, Ross, Donnellan (bib30) 2014; 15 Martin, Bonneterre, Geyer (bib10) 2013; 49 Weinstein, Joe (bib17) 2008; 68 Jankowitz, Abraham, Tan (bib33) 2013; 72 Fleiss (bib18) 1986; 7 Awada A, Colomer R, Inoue K, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic HER2-positive breast cancer: the NEfERT-T randomized clinical trial. Perez, Suman, Davidson (bib11) 2011; 29 Slamon, Clark, Wong, Levin, Ullrich, McGuire (bib1) 1987; 235 Gianni, Eiermann, Semiglazov (bib20) 2010; 375 Perez, Romond, Suman (bib2) 2014; 32 Pestalozzi, Holmes, de Azambuja (bib28) 2013; 14 Nahta, Esteva (bib9) 2006; 8 Eton, Cella, Yost (bib34) 2004; 57 Blackwell, Burstein, Storniolo (bib16) 2010; 28 de Azambuja, Holmes, Piccart-Gebhart (bib22) 2014; 15 Pickard, Neary, Cella (bib35) 2007; 5 Gianni, Dafni, Gelber (bib3) 2011; 12 Romond, Perez, Bryant (bib37) 2005; 353 Goldhirsch, Gelber, Piccart-Gebhart (bib5) 2013; 382 (in press). Canonici, Gijsen, Mullooly (bib27) 2013; 4 Slamon, Eiermann, Robert (bib12) 2009 Wang, Morrison, Gillihan (bib14) 2011; 13 Gianni, Pienkowski, Im (bib21) 2012; 13 Wong, Fracasso, Bukowski (bib7) 2009; 15 Besse, Soria, Yao (bib31) 2014; 25 Mann, Johnson, Kelly, Sridhara, Williams, Pazdur (bib38) 2005; 11 Nahta, O'Regan (bib25) 2012; 135 Dowsett, Harper-Wynne, Boeddinghaus (bib24) 2001; 61 Kurokawa, Lenferink, Simpson (bib26) 2000; 60 Gajria, Modi, Saura (bib32) 2015; 75 Piccart-Gebhart, Procter, Leyland-Jones (bib36) 2005; 353 Burstein, Sun, Dirix (bib8) 2010; 28 Slamon, Eiermann, Robert (bib4) 2011; 365 Weinstein, Joe (bib13) 2006; 3 Untch, Gelber, Jackisch (bib19) 2008; 19 Wong (10.1016/S1470-2045(15)00551-3_bib7) 2009; 15 Blackwell (10.1016/S1470-2045(15)00551-3_bib16) 2010; 28 Gianni (10.1016/S1470-2045(15)00551-3_bib20) 2010; 375 Perez (10.1016/S1470-2045(15)00551-3_bib2) 2014; 32 Eton (10.1016/S1470-2045(15)00551-3_bib34) 2004; 57 Slamon (10.1016/S1470-2045(15)00551-3_bib1) 1987; 235 de Azambuja (10.1016/S1470-2045(15)00551-3_bib22) 2014; 15 Martin (10.1016/S1470-2045(15)00551-3_bib10) 2013; 49 10.1016/S1470-2045(15)00551-3_bib29 Besse (10.1016/S1470-2045(15)00551-3_bib31) 2014; 25 Piccart-Gebhart (10.1016/S1470-2045(15)00551-3_bib36) 2005; 353 von Minckwitz (10.1016/S1470-2045(15)00551-3_bib15) 2009; 27 Untch (10.1016/S1470-2045(15)00551-3_bib19) 2008; 19 Joensuu (10.1016/S1470-2045(15)00551-3_bib6) 2009; 27 Mann (10.1016/S1470-2045(15)00551-3_bib38) 2005; 11 Gianni (10.1016/S1470-2045(15)00551-3_bib3) 2011; 12 Wang (10.1016/S1470-2045(15)00551-3_bib14) 2011; 13 Romond (10.1016/S1470-2045(15)00551-3_bib37) 2005; 353 Perez (10.1016/S1470-2045(15)00551-3_bib11) 2011; 29 Slamon (10.1016/S1470-2045(15)00551-3_bib4) 2011; 365 Gianni (10.1016/S1470-2045(15)00551-3_bib21) 2012; 13 Burstein (10.1016/S1470-2045(15)00551-3_bib8) 2010; 28 Nahta (10.1016/S1470-2045(15)00551-3_bib25) 2012; 135 Pickard (10.1016/S1470-2045(15)00551-3_bib35) 2007; 5 Slamon (10.1016/S1470-2045(15)00551-3_bib12) Weinstein (10.1016/S1470-2045(15)00551-3_bib13) 2006; 3 Pestalozzi (10.1016/S1470-2045(15)00551-3_bib28) 2013; 14 Gajria (10.1016/S1470-2045(15)00551-3_bib32) 2015; 75 Nahta (10.1016/S1470-2045(15)00551-3_bib9) 2006; 8 Kurokawa (10.1016/S1470-2045(15)00551-3_bib26) 2000; 60 Canonici (10.1016/S1470-2045(15)00551-3_bib27) 2013; 4 Goldhirsch (10.1016/S1470-2045(15)00551-3_bib5) 2013; 382 Dowsett (10.1016/S1470-2045(15)00551-3_bib24) 2001; 61 Weinstein (10.1016/S1470-2045(15)00551-3_bib17) 2008; 68 Fleiss (10.1016/S1470-2045(15)00551-3_bib18) 1986; 7 Jankowitz (10.1016/S1470-2045(15)00551-3_bib33) 2013; 72 De Laurentiis (10.1016/S1470-2045(15)00551-3_bib23) 2005; 11 Andreyev (10.1016/S1470-2045(15)00551-3_bib30) 2014; 15 26874902 - Lancet Oncol. 2016 Mar;17(3):268-70 27301039 - Lancet Oncol. 2016 May;17(5):e176-7 |
| References_xml | – volume: 29 start-page: 4491 year: 2011 end-page: 4497 ident: bib11 article-title: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer publication-title: J Clin Oncol – volume: 3 start-page: 448 year: 2006 end-page: 457 ident: bib13 article-title: Mechanisms of disease: oncogene addiction—a rationale for molecular targeting in cancer therapy publication-title: Nat Clin Pract Oncol – volume: 7 start-page: 267 year: 1986 end-page: 275 ident: bib18 article-title: Analysis of data from multiclinic trials publication-title: Control Clin Trials – volume: 28 start-page: 1301 year: 2010 end-page: 1307 ident: bib8 article-title: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer publication-title: J Clin Oncol – volume: 382 start-page: 1021 year: 2013 end-page: 1028 ident: bib5 article-title: 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial publication-title: Lancet – volume: 57 start-page: 898 year: 2004 end-page: 910 ident: bib34 article-title: A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale publication-title: J Clin Epidemiol – volume: 13 start-page: R121 year: 2011 ident: bib14 article-title: Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers—role of estrogen receptor and HER2 reactivation publication-title: Breast Cancer Res – volume: 60 start-page: 5887 year: 2000 end-page: 5894 ident: bib26 article-title: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells publication-title: Cancer Res – volume: 235 start-page: 177 year: 1987 end-page: 182 ident: bib1 article-title: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene publication-title: Science – volume: 11 start-page: 5671 year: 2005 end-page: 5677 ident: bib38 article-title: Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen publication-title: Clin Cancer Res – volume: 5 start-page: 70 year: 2007 ident: bib35 article-title: Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer publication-title: Health Qual Life Outcomes – volume: 135 start-page: 39 year: 2012 end-page: 48 ident: bib25 article-title: Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers publication-title: Breast Cancer Res Treat – volume: 68 start-page: 3077 year: 2008 end-page: 3080 ident: bib17 article-title: Oncogene addiction publication-title: Cancer Res – volume: 19 start-page: 1090 year: 2008 end-page: 1096 ident: bib19 article-title: Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial publication-title: Ann Oncol – volume: 375 start-page: 377 year: 2010 end-page: 384 ident: bib20 article-title: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2 negative cohort publication-title: Lancet – volume: 14 start-page: 244 year: 2013 end-page: 248 ident: bib28 article-title: CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01) publication-title: Lancet Oncol – volume: 15 start-page: e447 year: 2014 end-page: e460 ident: bib30 article-title: Guidance on the management of diarrhoea during cancer chemotherapy publication-title: Lancet Oncol – volume: 13 start-page: 25 year: 2012 end-page: 32 ident: bib21 article-title: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial publication-title: Lancet Oncol – volume: 4 start-page: 1592 year: 2013 end-page: 1605 ident: bib27 article-title: Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer publication-title: Oncotarget – volume: 353 start-page: 1659 year: 2005 end-page: 1672 ident: bib36 article-title: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer publication-title: N Engl J Med – volume: 353 start-page: 1673 year: 2005 end-page: 1684 ident: bib37 article-title: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer publication-title: N Engl J Med – volume: 11 start-page: 4741 year: 2005 end-page: 4748 ident: bib23 article-title: A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer publication-title: Clin Cancer Res – volume: 15 start-page: 2552 year: 2009 end-page: 2558 ident: bib7 article-title: A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors publication-title: Clin Cancer Res – volume: 28 start-page: 1124 year: 2010 end-page: 1130 ident: bib16 article-title: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer publication-title: J Clin Oncol – reference: Awada A, Colomer R, Inoue K, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic HER2-positive breast cancer: the NEfERT-T randomized clinical trial. – volume: 25 start-page: 1 year: 2014 end-page: 41 ident: bib31 article-title: Neratinib with or without temsirolimus in patients with non-small cell lung cancer (NSCLC) carrying publication-title: Ann Oncol – volume: 49 start-page: 3763 year: 2013 end-page: 3772 ident: bib10 article-title: A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer publication-title: Eur J Cancer – year: 2009 ident: bib12 article-title: BCIRG 006 Phase III trial comparing AC→T with AC→TH and with TCH in the adjuvant treatment of HER2-amplified early breast cancer patients: third planned efficacy analysis – volume: 15 start-page: 1137 year: 2014 end-page: 1146 ident: bib22 article-title: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response publication-title: Lancet Oncol – volume: 72 start-page: 1205 year: 2013 end-page: 1212 ident: bib33 article-title: Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study publication-title: Cancer Chemother Pharmacol – volume: 12 start-page: 236 year: 2011 end-page: 244 ident: bib3 article-title: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial publication-title: Lancet Oncol – volume: 365 start-page: 1273 year: 2011 end-page: 1283 ident: bib4 article-title: Adjuvant trastuzumab in HER2-positive breast cancer publication-title: N Engl J Med – volume: 61 start-page: 8452 year: 2001 end-page: 8458 ident: bib24 article-title: HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer publication-title: Cancer Res – volume: 27 start-page: 5685 year: 2009 end-page: 5692 ident: bib6 article-title: Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial publication-title: J Clin Oncol – volume: 8 start-page: 215 year: 2006 ident: bib9 article-title: HER2 therapy: molecular mechanisms of trastuzumab resistance publication-title: Breast Cancer Res – volume: 27 start-page: 1999 year: 2009 end-page: 2006 ident: bib15 article-title: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study publication-title: J Clin Oncol – volume: 32 start-page: 3744 year: 2014 end-page: 3752 ident: bib2 article-title: Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831 publication-title: J Clin Oncol – reference: (in press). – volume: 75 year: 2015 ident: bib32 article-title: A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy publication-title: Cancer Res – volume: 8 start-page: 215 year: 2006 ident: 10.1016/S1470-2045(15)00551-3_bib9 article-title: HER2 therapy: molecular mechanisms of trastuzumab resistance publication-title: Breast Cancer Res doi: 10.1186/bcr1612 – volume: 12 start-page: 236 year: 2011 ident: 10.1016/S1470-2045(15)00551-3_bib3 article-title: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70033-X – volume: 365 start-page: 1273 year: 2011 ident: 10.1016/S1470-2045(15)00551-3_bib4 article-title: Adjuvant trastuzumab in HER2-positive breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa0910383 – volume: 28 start-page: 1301 year: 2010 ident: 10.1016/S1470-2045(15)00551-3_bib8 article-title: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2009.25.8707 – volume: 15 start-page: 1137 year: 2014 ident: 10.1016/S1470-2045(15)00551-3_bib22 article-title: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70320-1 – volume: 15 start-page: e447 year: 2014 ident: 10.1016/S1470-2045(15)00551-3_bib30 article-title: Guidance on the management of diarrhoea during cancer chemotherapy publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70006-3 – volume: 11 start-page: 4741 year: 2005 ident: 10.1016/S1470-2045(15)00551-3_bib23 article-title: A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-2569 – volume: 28 start-page: 1124 year: 2010 ident: 10.1016/S1470-2045(15)00551-3_bib16 article-title: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2008.21.4437 – volume: 68 start-page: 3077 year: 2008 ident: 10.1016/S1470-2045(15)00551-3_bib17 article-title: Oncogene addiction publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-3293 – volume: 72 start-page: 1205 year: 2013 ident: 10.1016/S1470-2045(15)00551-3_bib33 article-title: Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-013-2262-2 – volume: 235 start-page: 177 year: 1987 ident: 10.1016/S1470-2045(15)00551-3_bib1 article-title: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene publication-title: Science doi: 10.1126/science.3798106 – volume: 27 start-page: 5685 year: 2009 ident: 10.1016/S1470-2045(15)00551-3_bib6 article-title: Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial publication-title: J Clin Oncol doi: 10.1200/JCO.2008.21.4577 – volume: 25 start-page: 1 year: 2014 ident: 10.1016/S1470-2045(15)00551-3_bib31 article-title: Neratinib with or without temsirolimus in patients with non-small cell lung cancer (NSCLC) carrying HER2 somatic mutations: an international randomized phase II study publication-title: Ann Oncol doi: 10.1093/annonc/mdu438.47 – volume: 135 start-page: 39 year: 2012 ident: 10.1016/S1470-2045(15)00551-3_bib25 article-title: Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-012-2067-8 – volume: 29 start-page: 4491 year: 2011 ident: 10.1016/S1470-2045(15)00551-3_bib11 article-title: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2011.36.7045 – volume: 375 start-page: 377 year: 2010 ident: 10.1016/S1470-2045(15)00551-3_bib20 publication-title: Lancet doi: 10.1016/S0140-6736(09)61964-4 – volume: 13 start-page: 25 year: 2012 ident: 10.1016/S1470-2045(15)00551-3_bib21 article-title: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70336-9 – volume: 61 start-page: 8452 year: 2001 ident: 10.1016/S1470-2045(15)00551-3_bib24 article-title: HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer publication-title: Cancer Res – volume: 57 start-page: 898 year: 2004 ident: 10.1016/S1470-2045(15)00551-3_bib34 article-title: A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2004.01.012 – ident: 10.1016/S1470-2045(15)00551-3_bib12 – volume: 60 start-page: 5887 year: 2000 ident: 10.1016/S1470-2045(15)00551-3_bib26 article-title: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells publication-title: Cancer Res – volume: 19 start-page: 1090 year: 2008 ident: 10.1016/S1470-2045(15)00551-3_bib19 article-title: Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial publication-title: Ann Oncol doi: 10.1093/annonc/mdn005 – volume: 32 start-page: 3744 year: 2014 ident: 10.1016/S1470-2045(15)00551-3_bib2 article-title: Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831 publication-title: J Clin Oncol doi: 10.1200/JCO.2014.55.5730 – volume: 353 start-page: 1659 year: 2005 ident: 10.1016/S1470-2045(15)00551-3_bib36 article-title: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa052306 – volume: 353 start-page: 1673 year: 2005 ident: 10.1016/S1470-2045(15)00551-3_bib37 article-title: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa052122 – volume: 15 start-page: 2552 year: 2009 ident: 10.1016/S1470-2045(15)00551-3_bib7 article-title: A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-1978 – volume: 5 start-page: 70 year: 2007 ident: 10.1016/S1470-2045(15)00551-3_bib35 article-title: Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer publication-title: Health Qual Life Outcomes doi: 10.1186/1477-7525-5-70 – volume: 27 start-page: 1999 year: 2009 ident: 10.1016/S1470-2045(15)00551-3_bib15 article-title: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study publication-title: J Clin Oncol doi: 10.1200/JCO.2008.19.6618 – volume: 11 start-page: 5671 year: 2005 ident: 10.1016/S1470-2045(15)00551-3_bib38 article-title: Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-0354 – ident: 10.1016/S1470-2045(15)00551-3_bib29 doi: 10.1001/jamaoncol.2016.0237 – volume: 49 start-page: 3763 year: 2013 ident: 10.1016/S1470-2045(15)00551-3_bib10 article-title: A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer publication-title: Eur J Cancer doi: 10.1016/j.ejca.2013.07.142 – volume: 7 start-page: 267 year: 1986 ident: 10.1016/S1470-2045(15)00551-3_bib18 article-title: Analysis of data from multiclinic trials publication-title: Control Clin Trials doi: 10.1016/0197-2456(86)90034-6 – volume: 382 start-page: 1021 year: 2013 ident: 10.1016/S1470-2045(15)00551-3_bib5 article-title: 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(13)61094-6 – volume: 4 start-page: 1592 year: 2013 ident: 10.1016/S1470-2045(15)00551-3_bib27 article-title: Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer publication-title: Oncotarget doi: 10.18632/oncotarget.1148 – volume: 75 issue: suppl 9 year: 2015 ident: 10.1016/S1470-2045(15)00551-3_bib32 article-title: A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy publication-title: Cancer Res – volume: 3 start-page: 448 year: 2006 ident: 10.1016/S1470-2045(15)00551-3_bib13 article-title: Mechanisms of disease: oncogene addiction—a rationale for molecular targeting in cancer therapy publication-title: Nat Clin Pract Oncol doi: 10.1038/ncponc0558 – volume: 13 start-page: R121 year: 2011 ident: 10.1016/S1470-2045(15)00551-3_bib14 article-title: Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers—role of estrogen receptor and HER2 reactivation publication-title: Breast Cancer Res doi: 10.1186/bcr3067 – volume: 14 start-page: 244 year: 2013 ident: 10.1016/S1470-2045(15)00551-3_bib28 article-title: CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01) publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70017-2 – reference: 27301039 - Lancet Oncol. 2016 May;17(5):e176-7 – reference: 26874902 - Lancet Oncol. 2016 Mar;17(3):268-70 |
| SSID | ssj0017105 |
| Score | 2.6443887 |
| Snippet | Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We... SummaryBackgroundNeratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 367 |
| SubjectTerms | Abdomen Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - surgery Cancer therapies Chemotherapy Chemotherapy, Adjuvant Corporate sponsorship Data collection Disease-Free Survival Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Follow-Up Studies Hematology, Oncology, and Palliative Medicine Humans Internationality Kaplan-Meier Estimate Mastectomy - methods Medical prognosis Middle Aged Neoplasm Invasiveness - pathology Neoplasm Staging Pain Population Proportional Hazards Models Quinolines - administration & dosage Quinolines - adverse effects Receptor, ErbB-2 - metabolism Survival Analysis Trastuzumab - administration & dosage Trastuzumab - adverse effects Treatment Outcome Tumors Womens health |
| Title | Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1470204515005513 https://www.clinicalkey.es/playcontent/1-s2.0-S1470204515005513 https://dx.doi.org/10.1016/S1470-2045(15)00551-3 https://www.ncbi.nlm.nih.gov/pubmed/26874901 https://www.proquest.com/docview/1771216898 https://www.proquest.com/docview/1773424676 |
| Volume | 17 |
| WOSCitedRecordID | wos000371234900049&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7X7 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & allied health premium. customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7RV dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: BENPR dateStart: 20000901 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database (subscription) customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 8C1 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELboFiEuvB8LpTISh1aqaew4scMFQbVVL6yqpaDerPixYtGSLJukEvwv_h9jx5teKEXiYimbfBsrmcx8tj_PIPRKUz0v5pkjORMJ4cDpwQ8mKTF0zl1JuZFahmITYjqV5-fFaZxwa6KscuMTg6O2tfFz5IdUCMpoLgv5dvWd-KpRfnU1ltDYQts-Uxkfoe33k-npbFhHEL2IkXLoiE-8frmH5_Dj8OMezfZ9LipK0qui01XsM0Sh47v_2_976E7kn_hdbzD30Q1XPUC3PsQV9ofo19RnWV5UC41D-XDcrsum7X5230pNfMizuLRfO-DfLe73bv3AiwrH9KwN9vO6-GQyY6SXg104rL3uvcXG29ca700gGkwnZ_tvcImDnDHoQ90BhqhpazA7Zw-wrTu9dEQDCYajIBzTNYm6-qW_YvUFOoNTHMqOPEKfjidnRycklnYgJktYS6TkOhfMOOqSzPE5h4FXWTBq05LnzNkCWJ6VwsHAnXEhCptmRiQlz5gDpKTpYzSq6so9RTjJdKZhID-3ueHUuII7ql2qqTWSW0nHiG9eqTIx77kvv7FUg8DNW4LylqBopoIlqHSMXg-wVZ_44zpAvrEXtdnVCn5YQWi6Dij-BHRN9CaNoqphKunRHgwk3kMBKQdkJEw9EfqXm-5szFRd3mew0TF6OZyGF-8XkcrK1V24JuUMwms-Rk_6T2F4PiyXggPBfPb3P3-ObgPtzHsl3w4atevOvUA3zUW7aNa7aEvMPvv2XIRWQiuP6G78tH8DpIJMUQ |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQcCF92OhgJFAaqWaxo4TO0gIobLVVm1XCBapNxM_VixakmWTFJUfxY3_xzivXijl0gPHbDJJ1pnHN8k3Mwg901RPk2nkSMxEQDhgevCDQUgMnXKXUm6klvWwCTEey8PD5N0K-tnVwnhaZecTa0dtc-PfkW9RISijsUzk68U34qdG-a-r3QiNRi323PF3SNmKV7tv4fk-Z2xnONkekXaqADFRwEoiJdexYMZRF0SOTzlg_jRh1IYpj5mzCQAMK4WDnJFxIRIbRkYEKY-YA0lJQzjvBXTRd7LzyZ7c7iklVDSUScrhb_s27ycVQ1sf-h_XabThO19REp4WC0_DunXM27n-v63WDXStRdf4TWMON9GKy26hywctf-A2-jX2PaRn2Uzjejg6LpdpUVY_qq-pJj6gW5zaLxVkFyVuKtOO8SzDbfPZAvu31ng0fM9IQ3Y7clh7Vn-JjbeeJV4fQqwbDycbL3GKa7JmzX51mxgwgc3BqJzdxDav9NwRDRAftmpanM5JWzUw90csPsPN4BDXQ1XuoI_nsmh30WqWZ-4-wkGkIy2knNrYcGpcwh3VLtTUGsmtpAPEOxVSpu3q7oeLzFVP3_Oap7zmKRqpWvNUOEAverFF09bkLIG400_V1exClFEQeM8SFH8SdEXrKwtFVcFU0Eh7YUhRvChIyl6yhYMNzPuXi651ZqFOrtPbxAA97XfDg_efyNLM5VV9TMgZgId4gO41ptevD4ul4ACfH_z95E_QldHkYF_t7473HqKrALDjhrO4hlbLZeUeoUvmqJwVy8e188Do03nb328plqCQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQBMv3C-FAUYCaZNmGjtO7CAhhLZWmwbVBEPam4kvEUWlKU0yNP4XL_w6jnPbC2O87IHHtvmSyjmXz8l3zkHomaY6S7LIkZiJgHDg9BAHg5AYmnGXUm6klvWwCTGZyKOj5GAF_epqYbyssouJdaC2ufHPyIdUCMpoLBM5zFpZxMHO-PXiG_ETpPyb1m6cRmMi--7kO2zfild7O3CvnzM2Hh1u75J2wgAxUcBKIiXXsWDGURdEjmcc-H-aMGrDlMfM2QTIhpXCwf6RcSESG0ZGBCmPmAOkpCGc9xK6LEKwYl-lvt3LS6ho5JOUwxL4lu-n1UPDD_2XGzTa9F2wKAnPyotn8d46_42v_88rdwNda1k3ftO4yU204ua30Nq7VldwG_2c-N7S0_lU43poOi6XaVFWP6qvqSY-0Vuc2i8V7DpK3FSsneDpHLdNaQvsn2bj3dF7RhoR3LHD2qv9S2y8Vy3xxghy4GR0uPkSp7gWcdaqWLeFgSvYHJzN2S1s80rPHNFA_eFTLZfTOWmrCWb-iMVn-DM4xPWwlTvo44Us2l20Os_n7j7CQaQjLaTMbGw4NS7hjmoXamqN5FbSAeKdOSnTdnv3Q0dmqpf1eStU3goVjVRthSocoBc9bNG0OzkPEHe2qrpaXsg-ChLyeUDxJ6Ar2hhaKKoKpoIG7cGwdfFQQMoe2dLEhv79y0XXOxdRp9fp_WOAnvY_w433r87Sucur-piQMyAV8QDda9ywXx8WS8GBVj_4-8mfoDVwO_V2b7L_EF0F3h03UsZ1tFouK_cIXTHH5bRYPq7jCEafLtr9fgM_eKlV |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neratinib+after+trastuzumab-based+adjuvant+therapy+in+patients+with+HER2-positive+breast+cancer+%28ExteNET%29%3A+a+multicentre%2C+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+3+trial&rft.jtitle=The+lancet+oncology&rft.au=Chan%2C+Arlene&rft.au=Delaloge%2C+Suzette&rft.au=Holmes%2C+Frankie+A&rft.au=Moy%2C+Beverly&rft.date=2016-03-01&rft.pub=Elsevier+Limited&rft.issn=1470-2045&rft.eissn=1474-5488&rft.volume=17&rft.issue=3&rft.spage=367&rft_id=info:doi/10.1016%2FS1470-2045%2815%2900551-3&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=3973690041 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204516X00034%2Fcov150h.gif |